HOME › Research Insight › Major Players in the Cell-Based Assay Market Considered New Product Launch as the Key Strategy to expand their global Footprint in the Market.
Major Players in the Cell-Based Assay Market Considered New Product Launch as the Key Strategy to expand their global Footprint in the Market.
Major players of the in cell-based assay market include BD Biosciences (U.S.), Danaher Corporation (U.S.), DiscoveRx (U.S.), EMD Millipore (Germany), GE Healthcare (U.K.), Life Technologies Corporation (U.S.), PerkinElmer (U.S.), and Promega Corporation (U.S.).
The global cell-based assay report covers close to 80 developments for 10 major players in the market between the years 2011 to February 2014. The new product launch is the key strategy followed by major players in cell-based assay market to enhance their existing portfolio. It accounted for more than half of the share that is 54% of the total number of strategies. Major players such as G.E. Healthcare (U.K.), Promega Corporation (U.S.), EMD Millipore (U.S.), BD Biosciences (U.S.), Danaher Corporation (U.S.), Cisbio Bioassays (U.S.) followed this strategy between 2011 and February 2014. In January 2014, Cisbio bioassays launched EPIgeneousTM cellular assays for detection of various histone levels such as Total H3, H3K36Me2 and H3K27Me3GE; the same time Promega Corporation launched GloMax Discover, a multimode plate reader system for cell-based assays. Majority of the companies are relishing the chunk of revenues generated from the developed markets but have also tapped the enormous potential of the emerging markets such as India and China.
Some companies are also focusing on agreements, collaborations and partnerships which contributed up to one fourth of the total strategy count. The major players involved in this section were DiscoveRx Corporation (U.S.), EMD Millipore (U.S.), GE Healthcare (U.K.), Promega Corporation (U.S.), Life Technologies Corporation (U.S.). Acquisition accounted for 11 % of the key growth strategies from 2011 to 2014, followed by other developments such as expansions and recognitions, which accounted for 10%.
The biggest challenge faced by most cell-based assay firms is the challenge of assay optimization. Most companies overcome this challenge by offering custom assay development services. This further intensifies the market competition, thereby bringing about changes in the market at an increasing speed.
Cell-based Assays Market by Product [Reagents & Assay Kits (Cytotoxicity, GPCR), Cell lines, Plate Readers, HCS, HTS, Software & Assay Development Services], Application (Drug Discovery, ADMET), End-user (Pharmaceutical, CRO) - Global Forecast to 2018.
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252